October provides a ONE, TWO punch in Multiple Myeloma Survival and Life Expectancy

The myeloma patient community definitely has two excellent programs coming in Octorber.  First we have Dr. Paul Richardson, the Clinical Director, Multiple Myeloma for the Dana Farber Cancer Institute. That Topic will be “To Transplant or not to Transplant, That is the Question?”  The second is the October Multiple Myeloma Support Group meeting which will feature Dr. Craig Hofmeister, assistant professor of Internal Medicine at Ohio State University Medical Center.  Dr. Hofmeister will be discussing The James Cancer Institutes effort to “Bring Survival Rate and Life Expectancy Data to Everyone”, the doctor, hospital, researchers and the patient. 


Dr. Paul Richardson

Dr. Richardson will be sharing with us the Dana Faber initiated Clinical Trial which has been designed to help finally answer the question of whether to transplant or not.  I have not seen the panel members more excited about one of our broadcasts, and this one just may be our best ever.  Dr. Richardson will be the special guest at the Myeloma Cure Panel broadcast of October 24th, at 6:00 pm EST. You can sign up for this panel if you CLICK HERE.  Dana Farber and Dr. Richardson has been one of my FAB FIVE myeloma institutions in the world, however I am like the Big Ten and have 7 on my list.  A brief bio follows:  

Dr. Paul Richardson of Harvard Medical School/ Dana-Farber Cancer Institute

Dr. Richardson is Associate Professor of Medicine at Harvard Medical School, as well as Clinical Director of the Jerome Lipper Center for Multiple Myeloma at the Dana-Farber Cancer Institute in Boston and Chairman of the American Myeloma Research Consortiom. He received his medical degree from the Medical College of St. Bartholomew’s Hospital, University of London, and completed residency training at Beth Israel Hospital. Dr. Richardson is board certified in Internal Medicine, Hematology and Medical Oncology.



Dr. Craig Hofmeister

Dr. Hofmeister will be the special guest on Pat Killingsworth’s Myeloma Support Group Meeting for October 29 at 4:00 pm EST. To sign up and for more information please CLICK HERE.
What Dr. Hofmeister has found is that there is an urgent need for the medical professionals (doctors, and researchers)  to have the tools to do their jobs.  One of those tools is to know and understand what outcomes have been achieved given a specific treatment protocol.  What is the life expectancy and survival rate of the program as a whole or by any which way the doctor chooses to slice and dice it?   As with many institutions, this data is not accumulated and made available to the doctors, and this is the initiative that Dr. Hofmeister and The James are determined to provide the medical profession.  To me this is a game changer.   Wouldn’t it be nice if one day you could get on your computer and find out which hospital in the USA or world has the best survival rate for high risk multiple myeloma with a  chromosome 17p deletion.  My hat is off to Dr. Hofmeister and his team for taking on this remarkable initiative.  A brief bio follows:

Dr. Craig Hofmeister  of Ohio State University Medical Center

Dr. Hofmeister is Assistant Professor of Internal Medicine at Ohio State University Medical Center. He is a clinical investigator with interest in experimental therapeutics in Multiple Myeloma. His team’s research focuses primarily on phase I/II drug development in myeloma with a focus on novel drugs. He is a member of the myeloma committees of the ALLIANCE cooperative group, Multiple Myeloma Research Consortium, and the Bone Marrow Transplant Clinical Trials Network. 

I am so excited to be part of both of these great myeloma programs.  I hope you will join up and as always may God Bless your families myeloma journey.

For more information on multiple myeloma go to the web site www.myelomasurvival.com or you can follow me on twitter at: https://twitter.com/grpetersen1